Scientific Advisory Board

Scientific Advisors

Advisor: Wafik S. El-Deiry, MD, PhD, FACP

Wakif S. El-Deiry, MD, PhD, FACP is the Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center in Philadelphia. Until September 2014 he was the Rose Dunlap Division Chair and Chief of Hematology-Oncology at Penn State University. In 2009, El-Deiry became one of 40 active American Cancer Society Research Professors. He earned MD/PhD degrees from the University of Miami School of Medicine and completed medicine residency and medical oncology fellowship at Johns Hopkins School of Medicine in Baltimore. Dr. El-Deiry's research has focused on the molecular and genetic mechanisms of cancer, cellular apoptosis and translational drug development research based on cancer drug resistance mechanisms. He is internationally recognized as a leader in molecular oncology and genetics, is highly cited with >60,000 citations in Google Scholar (H-index 107) and has been funded by the National Institutes of Health (NIH), the Howard Hughes Medical Institute (HHMI), the American Cancer Society (ACS), and the American Association for Cancer Resarch (AACR) for his work in studying the biology of tumor suppressor pathways and translational drug development. He is an editor for several leading scientific journals including Editor-in-Chief of Cancer Biology & Therapy, has published over 300 research articles in leading scientific journals and edited 5 books. El-Deiry was elected as a Member of the Johns Hopkins University Society of Scholars in 2014, is a member of the American Society for Clinical Investigation since 1999, the Association of American Physicians since 2008 and has served as President of the Interurban Clinical Club in 2013-2014. In 2017 he serves as the Chair of an NIH Study section on Basic Mechanisms of Cancer Therapeutics, as the Track Leader in Tumor Biology for the American Society of Clinical Oncology (ASCO) and as a Member of the ACS Council for Extramural Grants. His expertise in molecular genetics and clinical oncology are valuable in helping Morphotek steer its anti-cancer therapeutics programs and clinical studies.

Advisor: Kenneth Kinzler, Ph.D.

Kenneth W. Kinzler, Ph.D. is Professor of Oncology at the Johns Hopkins University School of Medicine, co-Director of the Ludwig Center at Johns Hopkins University and Associate Director for Basic Research for the Sidney Kimmel Comprehensive Cancer Center (SKCCC). He has produced classic studies of the genes causing human cancer including the discovery of APC, the gene that initiates virtually all colorectal tumors. He is also known for his development of genetic methods for analyzing gene expression and mutations in human cancer leading to his more recent work on defining the cancer genome and using released tumor DNA as a clinical biomarker. He has coauthored over 390 peer-reviewed articles on the molecular analyses of cancer and holds over 125 patents. He is a member of the National Academy of Sciences, National Academy of Medicine, National Academy of Inventors and is a Fellow of American Association of Cancer Research Academy. Dr. Kinzler is a co-inventor of morphogenics, and his knowledge in molecular genetics is a valuable resource for Morphotek's plathorm technology.  Participation by Dr. Kinzler as advisor does not constitute or imply endorsement by Johns Hopkins University or its affiliates.

Advisor: Bert Vogelstein, M.D.

Bert Vogelstein, M.D. is the Clayton Professor of Oncology and Pathology at the Johns Hopkins School of Medicine, and an investigator of the Howard Hughes Medical Institute. He is a member of the National Academy of Sciences and National Academy of Medicine. Dr. Vogelstein is currently the most highly cited scientist in the world. He is a co-inventor of morphogenics, and his knowledge in the molecular basis of genetic diversity serves as a valuable resource for Morphotek's platform technology. Participation by Dr. Vogelstein as advisor does not constitute or imply endorsement by Johns Hopkins University or its affiliates.